Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women

B. Bonanni, H. Johansson, S. Gandini, A. Guerrieri-Gonzaga, M. T. Sandri, F. Mariette, E. A. Lien, A. Decensi

Research output: Contribution to journalArticlepeer-review


The use of tamoxifen as a breast cancer preventive agent may be contraindicated by an increased risk of endometrial cancer and venous thromboembolic events, particularly in postmenopausal women. Since these estrogenic effects may be dose-related, a dose reduction may reduce toxicity. We have recently shown a comparable activity of lower doses of tamoxifen on putative surrogate biomarkers of cardiovascular disease and breast cancer. To provide further insight into the effect of tamox-ifen at low doses on the cardiovascular system, we compared the effect of three different doses on circulating levels of C-reactive protein (CRP), an independent risk marker for cardiovascular disease (CVD), which was lowered by tamoxifen at the standard dose of 20 mg day -1 in previous studies. We compared the changes in CRP after 2 months of either placebo (n = 24), or tamoxifen 10 mg alternate daily (n = 26), or 10 mg day -1 (n = 22), or 20 mg day -1 (n = 19) in healthy women aged 35-70 years. The median percent change was -2.2% (95% CI, -23.3 to 42.8) with placebo, -39.1 (95% CI, -59.9 to -28.7) with 10 mg alternate daily, -56.9% (95% CI, -68.6 to -38.4) with 10 mg day -1 and -42.9% (95% CI, -62.6to1.6)with 20 mg day -1 (P = 0.291 for the linear dose-response trend). Similar results were obtained when the data were classified according to blood tamoxifen concentrations, with a median reduction of 47% (95% CI, 65.5-36.3) for women with low tamoxifen concentrations (<30 ng mL -1). We conclude that tamoxifen at low doses is able to lower ultrasensitive CRP and that this might be associated witha beneicial effect on CVD.

Original languageEnglish
Pages (from-to)2149-2152
Number of pages4
JournalJournal of Thrombosis and Haemostasis
Issue number10
Publication statusPublished - Oct 2003


  • C-reactive protein
  • Cardiovascular disease
  • Tamoxifen

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)


Dive into the research topics of 'Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women'. Together they form a unique fingerprint.

Cite this